Zoetis (ZTS) Stock Price, News & Analysis

Zoetis logo
$80.85 -4.72 (-5.52%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$81.20 +0.35 (+0.44%)
As of 11/19/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Zoetis Stock (NYSE:ZTS)

Advanced

Key Stats

Today's Range
$80.71
▼
$85.13
50-Day Range
$69.07
▼
$88.60
52-Week Range
$68.77
▼
$132.49
Volume
4.71 million shs
Average Volume
4.64 million shs
Market Capitalization
$32.85 billion
P/E Ratio
13.75
Dividend Yield
2.62%
Price Target
$101.25
Consensus Rating
Hold

Company Overview

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer’s animal health business and became an independent public company in 2013. The company is headquartered in Parsippany, New Jersey, and is led by Chief Executive Officer Kristin Peck.

AI Generated. May Contain Errors.

Zoetis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

ZTS MarketRank™: 
4.598024420355 of 5 stars

Zoetis scored higher than 92% of companies evaluated by MarketBeat, and ranked 21st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zoetis has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 8 buy ratings, 12 hold ratings, and 1 sell rating.

  • Upside Potential

    Zoetis has a consensus price target of $101.25, representing about 25.2% upside from its current price of $80.85.

  • Amount of Analyst Coverage

    Zoetis has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Zoetis' stock forecast and price target.
  • Earnings Growth

    Earnings for Zoetis are expected to grow by 0.95% in the coming year, from $6.29 to $6.35 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zoetis is 12.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.28.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zoetis is 12.91, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 31.95.

  • Price to Earnings Growth Ratio

    Zoetis has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Zoetis has a P/B Ratio of 9.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.06% of the float of Zoetis has been sold short.
  • Short Interest Ratio / Days to Cover

    Zoetis has a short interest ratio ("days to cover") of 4.78.
  • Change versus previous month

    Short interest in Zoetis has recently decreased by 4.55%, indicating that investor sentiment is improving.
  • Dividend Yield

    Zoetis pays a meaningful dividend of 2.48%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Zoetis has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of Zoetis is 36.05%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Zoetis will have a dividend payout ratio of 33.39% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

  • Read more about Zoetis' dividend.
  • News Sentiment

    Zoetis has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Zoetis this week, compared to 8 articles on an average week.
  • Search Interest

    Only 11 people have searched for ZTS on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zoetis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.22% of the stock of Zoetis is held by insiders.

  • Percentage Held by Institutions

    92.80% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zoetis' insider trading history.
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZTS Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Zoetis Receives USDA License for 3-Disease Chicken Vaccine
Zoetis (ZTS) Climbed, So What Is Behind The Latest Attention?
Barclays Remains a Hold on Zoetis (ZTS)
See More Headlines

ZTS Stock Analysis - Frequently Asked Questions

Zoetis' stock was trading at $125.82 at the start of the year. Since then, ZTS stock has decreased by 35.7% and is now trading at $80.8480.

Zoetis Inc. (NYSE:ZTS) posted its quarterly earnings results on Thursday, November, 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.51 by $0.24. The company's quarterly revenue was down 1.3% on a year-over-year basis.
Read the conference call transcript
.

Zoetis subsidiaries include these companies: Jorox Pty, Virtual Recall, Fish Vet Group, Performance Livestock Analytics, Ethos Diagnostic Science, ZNLabs, Phoenix Lab, and others.

Zoetis (ZTS) raised $2.3 billion in an IPO on Friday, February 1st 2013. The company issued 99,015,000 shares at a price of $22.00-$25.00 per share.

Top institutional shareholders of Zoetis include State Street Corp (4.85%), Banque Pictet & Cie SA (0.43%), Worldquant Millennium Advisors LLC (0.26%) and Sumitomo Mitsui Trust Group Inc. (0.22%). Insiders that own company stock include Kristin C Peck, Paul Bisaro, Michael B Mccallister, Frank A Damelio, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zoetis investors own include NVIDIA (NVDA), Visa (V), Salesforce (CRM), Home Depot (HD), Advanced Micro Devices (AMD), Adobe (ADBE) and Mastercard (MA).

Company Calendar

Record date for 9/1 Dividend
7/20/2026
Ex-Dividend for 9/1 Dividend
7/20/2026
Dividend Payable
9/01/2026
Record date for 12/1 Dividend
10/30/2026
Ex-Dividend for 12/1 Dividend
10/30/2026
Last Earnings
11/05/2026
Today
11/20/2026
Dividend Payable
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:ZTS
CIK
1555280
Employees
14,500
Year Founded
1952

Price Target and Rating

High Price Target
$155.00
Low Price Target
$74.00
Potential Upside/Downside
+25.2%
Consensus Rating
Hold
Rating Score (0-4)
2.35
Research Coverage
20 Analysts

Profitability

EPS (Trailing Twelve Months)
$5.88
Trailing P/E Ratio
13.75
Forward P/E Ratio
12.73
P/E Growth
1.24
Net Income
$2.67 billion
Net Margins
26.15%
Pretax Margin
33.05%
Return on Equity
85.90%
Return on Assets
18.39%

Debt

Debt-to-Equity Ratio
2.51
Current Ratio
2.35
Quick Ratio
1.40

Sales & Book Value

Annual Sales
$9.47 billion
Price / Sales
3.47
Cash Flow
$7.15 per share
Price / Cash Flow
11.31
Book Value
$8.13 per share
Price / Book
9.94

Miscellaneous

Outstanding Shares
406,320,000
Free Float
405,422,000
Market Cap
$32.85 billion
Optionable
Optionable
Beta
0.67

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NYSE:ZTS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners